Highlight
Summary
About the Role
About You
- High school diploma or equivalent required.
- Minimum of 12 months in the health field or a combination of experience and education equivalent to this requirement preferred.
- Basic computer skills.
- Ability to lift, pull, or tug up to 40lbs.
- Ability to work routinely in a cold environment, -30°C.
- CPR certified or the ability to obtain certification preferred.
- Available to work extended shifts and weekends.
Benefits
- 401K plan with employer match and immediate vesting.
- Medical, Vision, Life and Dental Insurance.
- Pet Insurance.
- Company paid STD and LTD.
- Company Paid Holidays.
- Paid Time Off (within the first year).
- Tuition Assistance (after the first year).
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.